Business Context and Reporting Period
Company: Repligen Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Nine months ended December 31, 2009
Business Overview: Repligen is a biopharmaceutical company focused on developing novel therapeutics for central nervous system diseases and operating a bioprocessing business selling Protein A-based products for monoclonal antibody purification. The company also generates revenue from royalties related to the settlement of litigation with Bristol-Myers Squibb regarding the drug Orencia.
Key Financial Metrics
| Metric | Nine Months Ended Dec 31, 2009 | Nine Months Ended Dec 31, 2008 |
|---|---|---|
| Total Revenue | $16,098,796 | $24,767,766 |
| Net (Loss) Income | $(2,434,621) | $8,439,266 |
| Operating Loss | $(4,003,865) | $7,095,518 (Income) |
| Cash and Cash Equivalents | $5,318,900 | $14,987,843 (End of Period 2008) |
| Total Marketable Securities | $56,127,360 | $58,919,154 |
| Working Capital | $51,384,529 | $50,234,803 |
| Net Cash Used in Operating Activities | $(2,085,053) | $6,402,162 (Provided) |
Debt and Liquidity: The company reported total liabilities of $3,992,392, consisting primarily of current liabilities ($3,937,441). There are no significant long-term debt obligations listed, with long-term liabilities totaling only $54,951. Total cash, cash equivalents, and marketable securities stood at approximately $61.4 million as of December 31, 2009.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 35% ($8.7 million) compared to the prior year. This was driven by a 32% drop in bioprocessing product sales ($3.7 million decrease) and a significant reduction in royalty revenue from Bristol-Myers Squibb ($4.9 million decrease), which included a one-time $5 million settlement payment in the prior year.
- Profitability Shift: The company swung from a net income of $8.4 million in the prior year to a net loss of $2.4 million. This was primarily due to the revenue decline and a 32% increase in Research and Development (R&D) expenses.
- Expense Increases: R&D expenses rose by $2.6 million (32%) due to new licensing agreements (FSMA for Spinal Muscular Atrophy) and increased spending on Friedreich's ataxia and other clinical trials. Selling, General, and Administrative (SG&A) expenses increased by 17% due to headcount expansion.
- Cash Flow: Operating cash flow turned negative, consuming $2.1 million, compared to generating $6.4 million in the prior year. This was offset by net redemptions of marketable securities ($2.8 million) in investing activities.
Guidance, Outlook, and Risks
Management Commentary: Management expects future revenue to be limited to bioprocessing products, Bristol royalties, and research grants. They believe current cash and investment balances are adequate to meet needs absent acquisitions. The company plans to continue investing in R&D and evaluating strategic transactions.
Key Risks and Contingencies:
- Revenue Concentration: Bristol-Myers Squibb royalties represented 41% of total revenue for the nine-month period. The largest bioprocessing customer accounted for 37% of revenue.
- Development Uncertainty: The company cannot reliably estimate when therapeutic candidates will generate revenue. Future capital requirements depend on clinical trial success and regulatory approvals.
- Financing Needs: While currently liquid, the company may need to raise additional capital for acquisitions or R&D, which could result in equity dilution.
- Tax Position: A full valuation allowance has been provided against net operating losses and tax credits due to uncertainty regarding their realization, despite a $835,000 tax benefit recorded from the Worker, Homeownership, and Business Assistance Act of 2009.
Investor Verification Checklist
- Bristol Royalty Sustainability: Verify the trajectory of Orencia sales and the specific terms of the royalty agreement to assess the sustainability of this 41% revenue stream.
- R&D Burn Rate: Monitor the pace of spending on new programs (FSMA, Friedreich's ataxia) relative to cash reserves to determine runway without additional financing.
- Bioprocessing Demand: Assess the recovery of demand from key customers in the monoclonal antibody purification market, which drove the 32% revenue decline.
- Inventory Valuation: Review inventory levels ($2.1 million) and the company's assessment of obsolescence, given the "made-to-order" nature of their products.
- Tax Refund Timing: Confirm the receipt of the expected $835,000 tax refund from the 2009 Act upon the filing of the fiscal year 2010 tax return.